Dernières nouvelles pour Exact Sciences (NASDAQ:EXAS) Stock

Exact Sciences

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Exact Sciences Corporation - Common Stock

Exact Sciences Corp

Exasol AG

Barclays analyst Luke Sergott maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Overweight and raises the price target from $55 to $75.

News

Price Target

Analyst Ratings

EXAS

Barclays Maintains Overweight on Exact Sciences, Raises Price Target to $75

RBC Capital analyst Gerard Cassidy maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Sector Perform and raises the price target from $52 to $54.

RBC Capital Maintains Sector Perform on Exact Sciences, Raises Price Target to $54

U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Friday.
Shares of Trupanion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) rose sharply during Friday's session after the company reported better-than-expected first-quarter financial results and <a href="https://www.benzinga.com/quote/TRUP/earnings">raised its FY25 sales guidance</a>.
Trupanion reported quarterly loss of 3 cents per share which beat the analyst consensus estimate of loss of 5 cents per share. The company reported quarterly sales of $341.98 million which beat the analyst consensus estimate of $337.82 million.
Trupanion shares jumped 18.2% to $43.08 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares surged 30% to $9.60 after the company reported first-quarter financial results and beat its EPS and revenue estimates.</li>
<li>NPK International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPKI#NASDAQ">NPKI</a>) gained 26.6% to $7.65 after the company reported better-than-expected first-quarter financial results.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) rose 23.1% to $4.42.</li>
<li>Highest Performances Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPH#NASDAQ">HPH</a>) gained 23.1% to $7.20.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) rose 20.8% to $10.37.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) climbed 17.4% to $26.96.</li>
<li>iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) rose 17.4% to $127.43 after the company reported better-than-expected first-quarter results and raised its FY25 sales guidance</li>
<li>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) gained 15% to $460.50 after the company reported better-than-expected first-quarter financial results and raised its FY25 sales guidance.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) gained 13.7% to $79.87 following strong quarterly sales.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) jumped 12.4% to $7.74.</li>
<li>Maplebear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) gained 11.3% to $44.33 following first-quarter results.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) gained 11.1% to $52.40 after the company reported better-than-expected first-quarter sales results and raised its FY25 sales guidance.</li>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) gained 10.6% to $9.39.</li>
<li>MasTec, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) gained 6.4% to $142.68 following first-quarter results.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) rose 6.3% to $49.58.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45164963/how-to-earn-500-a-month-from-tyson-foods-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Tyson Foods Stock Ahead Of Q2 Earnings</a></li>
</ul>

Intraday Update

Markets

Movers

Trading Ideas

ACHR

ADPT

ASTS

CART

DUOL

DXCM

HOOD

IRTC

NPKI

PONY

TRUP

WOLF

Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday

Exact Sciences Corp.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NYSE">EXAS</a>) on Thursday reported a first-quarter 2025 EPS loss of 21 cents, down from a 37-cent loss a year ago, beating the analyst&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss estimate of 38 cents.</a>
The company reported quarterly sales of $706.78 million, up 11% year over year on a reported and core revenue basis, beating the consensus&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45149849/exact-sciences-announces-first-quarter-2025-results" rel="noreferrer noopener">estimate of $688.64 million</a>.
Screening revenue was $540 million, an increase of 14%, and Precision Oncology's revenue was $166.8 million, an increase of 2%&nbsp;or 4% on a core revenue basis.
"Our strong first quarter results pave the way for 2025 to mark our most transformative year yet," said Kevin Conroy, chairman and CEO. &#8220;With growing momentum in our commercial organization and improved profitability, we raised our full-year outlook and continue to build a foundation for sustained long-term growth."
Guidance: Exact Sciences raised its fiscal 2025 sales guidance from $3.02 billion-3.08 billion to $3.07 billion-3.12 billion versus the consensus of $3.06 billion.
The guidance includes a screening sales forecast of $2.39 billion—$2.43 billion, compared to previous guidance of $2.35 billion—$2.39 billion.
Precision Oncology sales are expected to be $680 million—$695 million, compared to prior guidance of $675 million—$695 million.
The company expects 2025 Adjusted EBITDA of $425 million—$455 million, up from previous guidance of $410 million—$440 million.
&#8220;Simply put, this was a solid first quarter out of the gate and we believe Exact is well positioned to continue to show modest upside throughout the year. This upside, coupled with pipeline catalysts like blood-based CRC screening test data later this summer, keep us positive on the long-term prospects,&#8221; William Blair writes.
Analyst Andrew F. Brackmann added, &#8220;In sum, this was a positive update and helped build support for a bullish thesis that can drive the stock higher over the course of the year. Shares trade at a very compelling forward revenue multiple of 3.5 times, leaving ample room for multiple expansion.&#8221;
William Blair reiterated <a href="https://www.benzinga.com/quote/EXAS/analyst-ratings" target="_blank" rel="noreferrer noopener">the Outperform rating</a>.
Price Action: At the last check on Friday, EXAS stock was up 11.3% at $52.50 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45158118/analyst-cautions-on-snap-as-meta-and-google-benefit-from-ad-spending-shifts" target="_blank" rel="noreferrer noopener">Analyst Cautions On Snap As Meta And Google Benefit From Ad Spending Shifts</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings

Guidance

Health Care

General

Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance

Evercore ISI Group analyst Vijay Kumar maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Outperform and raises the price target from $60 to $66.

Evercore ISI Group Maintains Outperform on Exact Sciences, Raises Price Target to $66

Baird analyst Catherine Schulte maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Outperform and raises the price target from $69 to $72.

Baird Maintains Outperform on Exact Sciences, Raises Price Target to $72

WIIM

Exact Sciences shares are trading higher after the company reported better-than-expected Q1 sales results and raised its FY25 sales guidance.

Shares of Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) rose sharply in pre-market trading after the company reported <a href="https://www.benzinga.com/quote/TWLO/earnings">better-than-expected first-quarter financial results.</a>
Twilio reported quarterly earnings of $1.14 per share which beat the analyst consensus estimate of $0.94 per share. The company reported quarterly sales of $1.17 billion which beat the analyst consensus estimate of $1.14 billion.
Twilio shares jumped 9.3% to $107.00 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>CN Energy Group. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>) rose 78.4% to $0.2529 in pre-market trading after gaining around 10% on Thursday.</li>
<li>Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) surged 57.1% to $0.3980 in pre-market trading after dipping over 18% on Thursday.</li>
<li>Classover Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDZ#NASDAQ">KIDZ</a>) gained 50.4% to $8.06 in pre-market trading. Classover Holdings shares jumped 366% on Thursday after the company announced it entered an equity purchase facility agreement with Solana Strategies Holdings.</li>
<li>Springview Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) surged 38% to $0.6781 in pre-market trading after gaining 11% on Thursday.</li>
<li>Greenlane Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) gained 25.5% to $0.0118 in pre-market trading after dipping 17% on Thursday.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) jumped 19.6% to $0.9325 in pre-market trading after gaining 13% on Thursday. The United States Patent and Trademark Office (USPTO) issued patent number 12,274,692 to Adial Pharmaceuticals' AD04 on Thursday.</li>
<li>NPK International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPKI#NYSE">NPKI</a>) gained 18.2% to $7.14 in pre-market trading after the company reported better-than-expected first-quarter financial results.</li>
<li>Society Pass Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPA#NASDAQ">SOPA</a>) rose 16.1% to $1.37 in pre-market trading after jumping over 42% on Thursday.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) gained 10.7% to $52.23 in pre-market trading after the company reported better-than-expected first-quarter sales results and raised its FY25 sales guidance.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) shares dipped 21.9% to $45.66 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>Healthcare Triangle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 19.8% to $0.2166 in pre-market trading after jumping 72% on Thursday.</li>
<li>Advantage Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) fell 18.9% to $1.07 in pre-market trading. Advantage Solutions will release financial results for the first quarter on May 12.</li>
<li>WW International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) shares fell 18.3% to $0.5927 in pre-market trading. WW International on Tuesday announced a pharmacy integration with Eli Lilly&#8217;s LillyDirect pharmacy provider, Gifthealth.</li>
<li>Pineapple Financial Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#NASDAQ">PAPL</a>) shares tumbled 18.1% to $0.16 in pre-market trading after falling 9% on Thursday.</li>
<li>Ardelyx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) dipped 16.4% to $4.57 in pre-market trading after the company reported worse-than-expected quarterly financial results.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) declined 16% to $192.35 in pre-market trading after the company issued fourth-quarter sales guidance below estimates.</li>
<li>LendingTree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) fell 12.9% to $47.14 in pre-market trading after the company reported worse-than-expected first-quarter sales results, issued second-quarter sales guidance below estimates, and cut its FY25 sales guidance.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) fell 2.9% to $207.24 in today's pre-market trading. Apple reported fiscal second-quarter revenue of $95.36 billion, beating analyst estimates of $94.53 billion. The Cupertino-based company reported second-quarter earnings of $1.65 per share, beating analyst estimates of $1.63 per share. The company&#8217;s CEO Tim Cook said that the tech giant expects a $900 million cost impact in the June quarter due to tariffs.</li>
<li>Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) fell 2.3% to $185.93 in pre-market trading. Amazon reported stronger-than-expected first-quarter financial results after market close Thursday. The company said it expects second-quarter net sales of $159 billion to $164 billion, up 7% to 11%. Analysts expect the company to have net sales of $160.91 billion in the quarter.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45133450/jim-cramer-this-consumer-cyclical-stock-is-a-one-trick-pony">Jim Cramer: This Consumer Cyclical Stock Is A &#8216;One-Trick Pony&#8217;</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

AAPL

ADIL

AMZN

ARDX

CNEY

GNLN

HCTI

KIDZ

PAPL

PLRZ

SOPA

SPHL

TEAM

TREE

TWLO

Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.38) by 44.74 percent. This is a 65 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $706.78 million which beat the analyst consensus estimate of $688.64 million by 2.64 percent. This is a 10.86 percent increase over sales of $637.52 million the same period last year.

Earnings Beats

CORRECTION: Exact Sciences Q1 Adj. EPS $(0.21) Beats $(0.38) Estimate, Sales $706.78M Beat $688.64M Estimate

<h3>Gainers</h3>
<ul>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock increased by 42.3% to $1.11 during Thursday's after-market session. The company's market cap stands at $7.2 million. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) shares moved upwards by 18.46% to $12.8. The company's market cap stands at $2.4 billion. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) stock increased by 11.47% to $6.9. The company's market cap stands at $109.0 million. The company's, Q1 earnings came out today. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares rose 8.93% to $0.84. The market value of their outstanding shares is at $3.7 million. </li>
<li>Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) shares moved upwards by 8.77% to $51.3. The market value of their outstanding shares is at $9.6 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Owlet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) shares increased by 8.76% to $4.22. The company's market cap stands at $69.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) shares decreased by 14.4% to $4.68 during Thursday's after-market session. The company's market cap stands at $1.1 billion. As per the press release, Q1 earnings came out today. </li>
<li>Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) shares declined by 13.59% to $37.09. The company's market cap stands at $4.3 billion. </li>
<li>AN2 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTX#NASDAQ">ANTX</a>) stock fell 12.1% to $1.09. The company's market cap stands at $32.8 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock fell 11.12% to $0.16. The market value of their outstanding shares is at $4.6 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock fell 11.12% to $0.24. The company's market cap stands at $10.8 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock fell 9.53% to $0.38. The company's market cap stands at $10.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMWL

ANTX

CYTK

ONMD

OWLT

SILO

SSII

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Thursday's After-Market Session

Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) raises FY2025 sales outlook from $3.02 billion-3.08 billion to $3.07 billion-3.12 billion.

Exact Sciences Raises FY2025 Sales Guidance from $3.02B-3.08B to $3.07B-3.12B

AAMI

ABNB

ACCO

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

APLE

APTV

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

ECVT

ELME

Earnings Scheduled For May 1, 2025

Robust research and data from multiple abstracts predict the Cologuard&#xAE; test as the top choice for screening average-risk adults 45 and older, and confirms adoption across diverse demographics
Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), a leading provider of cancer screening and diagnostic tests, today announced the company will present 15 abstracts during Digestive Disease Week (DDW) 2025, taking place May 3-6, 2025, in San Diego, California. The abstracts demonstrate high adherence and strong predicted preference for the Cologuard&#xAE; test along with abstracts on additional screening programs under development. The abstracts focused on the Cologuard test include data from more than half a million patients. DDW is the premier meeting for professionals working in gastroenterology, hepatology, GI endoscopy, and gastrointestinal surgery. DDW will make abstracts available <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Feposters.ddw.org%2Fddw%2F%3Fmenu%3D16%26browseby%3D3%26sortby%3D2%26ce_id%3D2855%26trend%3D19514%23%21&#x2A;menu%3D16&#x2A;browseby%3D3&#x2A;sortby%3D2&#x2A;ce_id%3D2855&#x2A;trend%3D19514&amp;esheet=54245104&amp;newsitemid=20250429379327&amp;lan=en-US&amp;anchor=on+their+website&amp;index=1&amp;md5=0094ce3adc3df26b2d0f6a67a7ce0090">on their website</a> on May 3.

Exact Sciences to Present Cologuard Test Adherence and Predicted Preference Data at Digestive Disease Week 2025

Exact Sciences launch of Oncodetect A New Test Designed To Detect Molecular Residual Disease (MRD) Across Multiple Solid Tumors

Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), a leading provider of cancer screening and diagnostic tests, today announced the publication of a comprehensive review in JAMA Oncology that strengthens the evidence supporting the Oncotype DX Breast Recurrence Score test. The peer-reviewed article titled, "Genomic Assays for Breast Cancer in Diverse Populations: Prognostic and Predictive Insights," affirms that the Oncotype DX test provides accurate and reliable information to help guide breast cancer treatment decisions across all racial and ethnic groups.
While breast cancer mortality has declined overall, non-Hispanic Black women continue to face a 40% higher mortality rate compared to non-Hispanic White womenI. The publication acknowledges these disparities and the need to better understand the complex factors behind them. Despite the prognostic differences between racial and ethnic minority groups, the Oncoytpe DX Breast Recurrence Score test accurately predicts chemotherapy benefit regardless of race or ethnicity. While these disparities highlight the need for broader systemic change, advancing precision oncology remains critical and tools like the Oncotype DX Breast Recurrence Score test ensure treatment decisions are guided by reliable data for every patient.
The largest real-world SEER registry analysis to date—spanning more than 171,000 breast cancer patients and presented at ASCO 2024—provides powerful new evidence that the Oncotype DX test accurately predicts chemotherapy benefit across all racial and ethnic groups. In this study, which is not part of the JAMA Oncology review, the Recurrence Score&#xAE; result predicted chemotherapy benefit in Hispanic, non-Hispanic Black and non-Hispanic White patientsII. These findings add to the body of evidence from key clinical trials—including NSABP&#x2A;-B20 and SWOG†-8814—which confirm that Oncotype DX is the only genomic test proven to predict chemotherapy benefit, the utility of which was further confirmed in randomized clinical trials including TAILORx and RxPONDER III,IV. With no racial or ethnic differences shown in its predictive value, the Oncotype DX test remains a trusted tool to help guide breast cancer treatment decisions for all patients.

Exact Sciences' Oncotype DX Test Gets New Backing in JAMA Oncology, Offers Reliable Insights for Diverse Breast Cancer Patients

Guggenheim analyst Subbu Nambi reiterates Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and maintains $60 price target.

Reiteration

Guggenheim Reiterates Buy on Exact Sciences, Maintains $60 Price Target

Barclays analyst Luke Sergott maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Overweight and lowers the price target from $65 to $55.

Barclays Maintains Overweight on Exact Sciences, Lowers Price Target to $55

Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $65.0, a high estimate of $73.00, and a low estimate of $52.00. Highlighting a 7.67% decrease, the current average has fallen from the previous average price target of $70.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1744286466_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Exact Sciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Anthony Petrone &#x7C;Mizuho &#x7C;Announces &#x7C;Outperform &#x7C; $60.00&#x7C;- &#x7C; 
&#x7C;Gerard Cassidy &#x7C;RBC Capital &#x7C;Announces &#x7C;Sector Perform &#x7C; $52.00&#x7C;- &#x7C; 
&#x7C;David Westenberg &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $70.00&#x7C;$75.00 &#x7C; 
&#x7C;Sung Ji Nam &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Outperform&#x7C; $73.00&#x7C;$70.00 &#x7C; 
&#x7C;Derik De Bruin &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $65.00&#x7C;$72.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $65.00&#x7C;$70.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Announces &#x7C;Overweight &#x7C; $70.00&#x7C;- &#x7C; 
&#x7C;Bruce Jackson &#x7C;Benchmark &#x7C;Maintains &#x7C;Buy &#x7C; $65.00&#x7C;$65.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exact Sciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Exact Sciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Exact Sciences's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>All You Need to Know About Exact Sciences</h2>
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
<h3>Understanding the Numbers: Exact Sciences's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Exact Sciences's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 10.29%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Exact Sciences's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -121.19%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -30.81%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Exact Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -13.64%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Exact Sciences's debt-to-equity ratio is below the industry average at 1.15, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Exact Sciences Stock: Analyst Perspectives (8 Ratings)

Mizuho analyst Anthony Petrone initiates coverage on Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Outperform rating and announces Price Target of $60.

Initiation

Mizuho Initiates Coverage On Exact Sciences with Outperform Rating, Announces Price Target of $60

Press Releases

Exact Sciences to Participate in March Investor Conferences

Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner

SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening

Exact Sciences Schedules First Quarter 2025 Earnings Call

JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups

Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test

Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025

Exact Sciences Announces First-Quarter 2025 Results

Exact Sciences to Participate in May Investor Conference

QTRX

SERA

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Barclays

RBC Capital

Evercore ISI Group

Baird

Guggenheim

Screenshot 2024-08-30 at 6.27.59 PM

Biotech

MYNZ

Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones

Screenshot 2024-06-20 at 6.58.26 PM

Mainz Biomed&#39;s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks

Screenshot 2024-06-04 at 5.31.42 PM

Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate

Comments

Exact Sciences

Actualités

Dernières nouvelles pour Exact Sciences (NASDAQ:EXAS) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL